Bio-Rad Laboratories Inc
$ 304.15
0.00%
11 Jun - close price
- Market Cap 8,139,540,000 USD
- Current Price $ 304.15
- High / Low $ 304.15 / 304.15
- Stock P/E 50.52
- Book Value 255.37
- EPS 6.02
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 321.12
- 52 Week Low 244.54
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
N/A
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-28 | 2025-07-30 | 2025-05-05 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-29 | 2023-10-27 | 2023-08-04 |
| Reported EPS | -19.5526 | 26.6548 | -12.6992 | 11.6718 | 2.2894 | -25.567 | 23.3401 | -76.2629 | 13.4533 | 3.1 | 2.33 | 3 |
| Estimated EPS | None | None | None | None | None | None | None | None | 2.99 | 2.84 | 2.76 | 2.64 |
| Surprise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.4633 | 0.26 | -0.43 | 0.36 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | 349.9431% | 9.1549% | -15.5797% | 13.6364% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO-B
2026-05-28 19:39:07
This article provides comprehensive financial data, news, and analyst ratings for Bio-Rad Laboratories Inc. (BIO). It includes key metrics such as stock price, market capitalization, P/E ratio, and recent insider transactions. The news section highlights recent events like activist investor interest, earnings reports, and analyst rating changes, offering a detailed overview of the company's market performance and corporate activities.
2026-05-28 14:40:59
Bio-Rad Laboratories shares are trading firmly above USD 300 on the NYSE, attracting investor attention due to an activist stake by Elliott Investment Management and recent price target updates. The company, a mid-cap life-science tools provider, has seen over 30% gains in the last year, reflecting renewed interest. Wells Fargo recently raised its price target to USD 310, indicating continued analyst engagement in the U.S. market.
2026-05-11 00:39:49
Bio-Rad released its Q1 2026 financial results, showing flat revenue growth and a downward revision of its full-year outlook due to tightening academic funding and geopolitical impacts on supply chains. The company is responding with tiered product launches, particularly expanding its ddPCR ecosystem, and focusing on organizational optimization. This strategic shift aims to address constrained spending in academic and biotech sectors while maintaining financial robustness.
2026-05-05 17:09:12
Ariel Investments' Ariel Focus Fund re-added Bio-Rad Laboratories (BIO) to its portfolio, highlighting the company's strong financial profile, diversified market footprint, and market leadership in life science research and clinical diagnostics. The fund emphasized Bio-Rad's rising operating margins, high recurring revenue, and competitive advantages, despite a cautious market outlook and the company not being among the most popular hedge fund stocks. Ariel maintains its focus on fundamentals-driven strategy amidst market volatility.
2026-05-04 09:40:20
This article provides a stock analysis of Bio-Rad Laboratories (NYSE:BIO), highlighting its valuation, future growth, past performance, financial health, and recent news. The company, which develops and distributes life science research and clinical diagnostic products, is currently trading at US$259.02, deemed 19.4% undervalued by analysts with a target of US$321.25. Recent updates include a cut in the 2026 outlook due to investment loss and geopolitical tensions, first-quarter 2026 earnings reporting a US$19.55 loss per share, and various analyst price target adjustments influenced by buybacks, intangible impairments, and updated financial assumptions.
2026-04-30 21:39:34
Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings, reporting an EPS of $1.89. The company demonstrated strong profitability with a net margin of 29.42% and a return on equity of 3.86%. Shares traded up by $22.45 to $299.45 following the report, with the company maintaining a market cap of $8.08 billion.
